524212 Stock Overview
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹64.05|
|52 Week High||₹111.75|
|52 Week Low||₹55.55|
|1 Month Change||-2.21%|
|3 Month Change||-6.29%|
|1 Year Change||-21.22%|
|3 Year Change||407.13%|
|5 Year Change||71.95%|
|Change since IPO||-65.63%|
Recent News & Updates
|524212||IN Pharmaceuticals||IN Market|
Return vs Industry: 524212 underperformed the Indian Pharmaceuticals industry which returned -12% over the past year.
Return vs Market: 524212 underperformed the Indian Market which returned 8.3% over the past year.
|524212 Average Weekly Movement||5.8%|
|Pharmaceuticals Industry Average Movement||5.9%|
|Market Average Movement||6.4%|
|10% most volatile stocks in IN Market||9.0%|
|10% least volatile stocks in IN Market||4.1%|
Stable Share Price: 524212 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 524212's weekly volatility (6%) has been stable over the past year.
About the Company
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury Fundamentals Summary
|524212 fundamental statistics|
Is 524212 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|524212 income statement (TTM)|
|Cost of Revenue||₹3.00b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||22.97|
|Net Profit Margin||15.01%|
How did 524212 perform over the long term?See historical performance and comparison
Is 524212 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524212?
Other financial metrics that can be useful for relative valuation.
|What is 524212's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 524212's PE Ratio compare to its peers?
|524212 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
JSLL Jeena Sikho Lifecare
500009 Ambalal Sarabhai Enterprises
PAR Par Drugs and Chemicals
531726 Panchsheel Organics
Price-To-Earnings vs Peers: 524212 is good value based on its Price-To-Earnings Ratio (2.8x) compared to the peer average (20x).
Price to Earnings Ratio vs Industry
How does 524212's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 524212 is good value based on its Price-To-Earnings Ratio (2.8x) compared to the Indian Pharmaceuticals industry average (22.6x)
Price to Earnings Ratio vs Fair Ratio
What is 524212's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||2.8x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524212's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 524212 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 524212 (₹64.05) is trading below our estimate of fair value (₹198.74)
Significantly Below Fair Value: 524212 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Wanbury forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanbury has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Wanbury performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524212 has a large one-off gain of ₹763.7M impacting its June 30 2022 financial results.
Growing Profit Margin: 524212 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 524212's earnings have grown significantly by 52.4% per year over the past 5 years.
Accelerating Growth: 524212 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524212 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.3%).
Return on Equity
High ROE: 524212's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Wanbury's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 524212 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 524212 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 524212 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 524212's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: 524212's debt is well covered by operating cash flow (51%).
Interest Coverage: 524212's interest payments on its debt are not well covered by EBIT (0.9x coverage).
Discover healthy companies
What is Wanbury current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 524212's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 524212's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 524212's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 524212's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 524212 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wanbury has no CEO, or we have no data on them.
Experienced Management: 524212's management team is seasoned and experienced (6.3 years average tenure).
Experienced Board: 524212's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Wanbury Limited's employee growth, exchange listings and data sources
- Name: Wanbury Limited
- Ticker: 524212
- Exchange: BSE
- Founded: 1988
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹2.094b
- Shares outstanding: 32.70m
- Website: https://www.wanbury.com
Number of Employees
- Wanbury Limited
- BSEL Tech Park, B-Wing
- 10th Floor
- Navi Mumbai
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.